US Pharma MarketingNodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand
NodThera rebrands to Rezera, plans Phase 3 trial in peripheral artery disease in 2027 with ~800 patients testing NLRP3 inhibitor ruvonoflast. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…
After tinkering with the biology of the broadly appealing anti-inflammatory NLRP3 pathway, NodThera is now plotting its pivotal trial plans for 2027.
The decade-old biotech said Wednesday it is rebranding to Rezera ...
Source: Endpoints News